Literature DB >> 24571808

Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma.

Naoto Sassa1, Masashi Kato, Yasuhito Funahashi, Motohiro Maeda, Satoshi Inoue, Momokazu Gotoh.   

Abstract

The authors present the first case report of pre-surgical axitinib treatment on primary renal tumor and vena cava thrombus. We report the case of a 78-year-old woman with renal cell carcinoma and inferior vena cava tumor thrombus, successfully downstaged with pre-surgical therapy with axitinib. A significant objective response was observed for tumor size and thrombus. After initiation of axitinib therapy, computed tomography showed a decrease, from 57 to 51 mm, in the maximal renal tumor diameter. The tumor thrombus had shortened to 42 mm and had moved to the inferior hepatic vein (Levels 4-3), thereby obviating the need for thoracotomy. The patient finally accepted surgical treatment. Our case was enabled to perform less surgery for advanced renal cell carcinoma with tumor thrombus using axitinib as a pre-surgical therapy.

Entities:  

Keywords:  IVC thrombus; axitinib; molecular target agents; pre-surgical; renal cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 24571808     DOI: 10.1093/jjco/hyu014

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

Review 1.  Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

Authors:  Adrian Husillos Alonso; Manuel Carbonero García; Carmen González Enguita
Journal:  World J Nephrol       Date:  2015-05-06

2.  Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava.

Authors:  Yoshimi Tanaka; Shingo Hatakeyama; Shogo Hosogoe; Toshikazu Tanaka; Itsuto Hamano; Ayumu Kusaka; Hiromich Iwamura; Naoki Fujita; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2017-07-27       Impact factor: 3.402

3.  Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.

Authors:  Hironori Fukuda; Tsunenori Kondo; Toshio Takagi; Jumpei Iizuka; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2017-04-01       Impact factor: 3.402

Review 4.  Overview on the role of preoperative therapy in the management of kidney cancer.

Authors:  T Assi; E El Rassy; F Farhat; J Kattan
Journal:  Clin Transl Oncol       Date:  2019-05-29       Impact factor: 3.405

Review 5.  The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma.

Authors:  Leonardo D Borregales; Mehrad Adibi; Arun Z Thomas; Christopher G Wood; Jose A Karam
Journal:  Ther Adv Urol       Date:  2015-11-20

Review 6.  Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma.

Authors:  Sarah P Psutka; Bradley C Leibovich
Journal:  Ther Adv Urol       Date:  2015-08

7.  Role of presurgical targeted molecular therapy in renal cell carcinoma with an inferior vena cava tumor thrombus.

Authors:  Cheng Peng; Liangyou Gu; Lei Wang; Qingbo Huang; Baojun Wang; Gang Guo; Yang Fan; Yu Gao; Xin Ma; Xu Zhang
Journal:  Onco Targets Ther       Date:  2018-04-06       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.